MRI contrast developer Epix Pharmaceuticals said that its shareholders have voted to approve its merger with Predix Pharmaceuticals Holdings of Lexington, MA, whose shareholders have also voted in favor of the transaction.
The firms expect that the merger will close tomorrow, according to the Cambridge, MA-based Epix.
The combined company will be known as Epix and is expected to continue to trade on the Nasdaq market under the symbol EPIX.
By AuntMinnie.com staff writers
August 15, 2006
Related Reading
Epix nears Australia approval for Vasovist, August 14, 2006
Epix grows revenues in Q2, August 7, 2006
FDA extends Epix's Vasovist appeal, July 31, 2006
Epix retains rights to EP-2104R, July 13, 2006
Epix files Vasovist appeal with FDA, July 4, 2006
Copyright © 2006 AuntMinnie.com
